Transgenic Mouse Genome Editing Core

项目概要（转基因小鼠基因组编辑核心） 转基因小鼠基因组编辑核心（TMGEC）已成为糖尿病研究的一个组成部分 自1997年以来，在宾夕法尼亚大学佩雷尔曼医学院担任中心（DRC）。TMGEC是 由遗传学系教授兼副主任道格拉斯爱泼斯坦博士指导。爱泼斯坦医生是一名 经验丰富的研究人员，在技术和实验方法方面具有相当的专业知识， 小鼠疾病模型，发育遗传学和基因组编辑。经验丰富的技术团队， 由Jean Richa博士领导，提供全方位转基因技术的专业知识，使TMGEC能够 定期推出新的和改进的服务。TMGEC提供的服务包括生成 通过直接基因组编辑（CRISPR/Cas9），将DNA显微注射到受精卵母细胞中， 创建转基因品系，通过胚胎干细胞注射到囊胚中产生嵌合小鼠。的 TMGEC还进行胚胎再衍生，胚胎和精子冷冻保存，体外受精（IVF）， 和集中低温保存储存。TMGEC采用最先进的激光调节技术， 促进IVF，并具有胞浆内精子注射能力，以补充IVF服务。新开发 在目前的资助期间，服务包括冷冻保存服务的主要扩展， 相应地扩大冷冻保存设施，整合CRISPR/Cas9直接基因组 用新建立的佩雷尔曼医学院CRISPR核心进行修改，并电穿孔DNA 和RNA进入胚胎，以增加通量并减少TMGEC服务的等待时间。近5 年，48名DRC研究人员使用TMGEC服务生成了225个独立的小鼠品系（主要由 CRISPR/Cas9编辑）和储存134个小鼠系（通过冷冻保存）。预计使用量将保持在 在未来五年内，这一数字将保持不变或增加。为设备提供额外的机构（非刚果民主共和国）支助 维护和设施基础设施升级和维护。广泛的合作网络 在刚果民主共和国内存在的重点是使用转基因小鼠模型的糖尿病，肥胖和 代谢紊乱刚果民主共和国调查人员之间的这些联合项目突出了TMGEC的作用， 一个重要的技术资源，也是刚果民主共和国调查人员之间合作研究的关键枢纽， 由众多的联合出版物和成功的资助申请所证明的， 由TMGEC存储和/或重新导出。

PROJECT SUMMARY (Transgenic Mouse Genome Editing Core) The Transgenic Mouse Genome Editing Core (TMGEC) has been an integral part of the Diabetes Research Center (DRC) at the Perelman School of Medicine, University of Pennsylvania since 1997. The TMGEC is directed by Dr. Douglas Epstein, PhD, Professor and Vice Chair, Department of Genetics. Dr. Epstein is an experienced investigator with considerable expertise in technologies and experimental approaches that center on mouse models of disease, developmental genetics, and genome editing. An experienced technical team, led by Dr. Jean Richa, provides expertise in a full range of transgenic technologies, enabling the TMGEC to regularly introduce new and improved services. Services provided by the TMGEC include the generation of genetically altered mice by direct genome editing (CRISPR/Cas9), DNA microinjection into fertilized oocytes to create transgenic lines, the generation of chimeric mice via embryonic stem cell injection into blastocysts. The TMGEC also carries out embryo re-derivation, embryo and sperm cryopreservation, in vitro fertilization (IVF), and centralized cryopreservation storage. The TMGEC uses state-of-the-art laser conditioning of the zona to facilitate IVF and has intracytoplasmic sperm injection capability to complement IVF services. Newly developed services during the current funding period include the major expansion of cryopreservation services with corresponding expansion of the cryopreservation facility, integration of CRISPR/Cas9 direct genome modifications with a newly established Perelman School of Medicine CRISPR core, and electroporation of DNA and RNA into embryos to increase throughput and decrease wait time for TMGEC services. In the past 5 years, 48 DRC investigators used TMGEC services to generate 225 independent mouse lines (primarily by CRISPR/Cas9 editing) and to store 134 mouse lines (by cryopreservation). Usage is expected to stay the same, or increase over the next five years. Additional Institutional (non-DRC) support is provided for equipment maintenance and facility infrastructure upgrades and maintenance. An extensive network of collaborations exist within the DRC focusing on the use of genetically modified mouse models of diabetes, obesity and metabolic disorders. These joint projects among DRC investigators highlight the role of the TMGEC not only as an essential technical resource but also as a key hub for collaborative research among DRC investigators, as exemplified by the numerous joint publications and successful grant applications arising from mice generated, stored, and/or re-derived by the TMGEC.